Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients

被引:0
作者
Thilo Bracht
Christian Mölleken
Maike Ahrens
Gereon Poschmann
Anders Schlosser
Martin Eisenacher
Kai Stühler
Helmut E. Meyer
Wolff H. Schmiegel
Uffe Holmskov
Grith L. Sorensen
Barbara Sitek
机构
[1] Ruhr-Universität Bochum,Medizinisches Proteom
[2] Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil,Center
[3] Heinrich-Heine-Universität,Department of Gastroenterology and Hepatology
[4] University of Southern Denmark,Molecular Proteomics Laboratory (MPL), Biologisch
来源
Journal of Translational Medicine | / 14卷
关键词
Hepatic fibrosis; Cirrhosis; Microfibrillar-associated protein 4; Serum biomarker; Hepatitis C; Direct acting antivirals;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 277 条
[1]  
Lavanchy D(2011)Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 107-115
[2]  
Hanafiah KM(2013)Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 1333-1342
[3]  
Groeger J(2014)Global epidemiology and genotype distribution of the hepatitis C virus infection J Hepatol 61 S45-S57
[4]  
Flaxman AD(2015)New kids on the block-step by step to an ideal HCV therapy Lancet 385 1050-1052
[5]  
Wiersma ST(2015)Electronic address eee: EASL recommendations on treatment of hepatitis C 2015 J Hepatol 63 199-236
[6]  
Gower E(2015)Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable Gut 64 1190-1191
[7]  
Estes C(2015)The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C Expert Rev Pharmacoecon Outcomes Res. 15 787-800
[8]  
Blach S(1999)Natural history of hepatitis C J Hepatol 31 17-24
[9]  
Razavi-Shearer K(2011)Biomarkers of liver fibrosis J Gastroenterol Hepatol 26 802-809
[10]  
Razavi H(2003)Sampling variability of liver fibrosis in chronic hepatitis C Hepatology 38 1449-1457